Scarica l'app Stockscreener
32.50
0.09%
-0.03
Dopo l'orario di chiusura:
32.50
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ENOV Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$32.53
Aprire:
$31.2
Volume 24 ore:
1.26M
Relative Volume:
1.39
Capitalizzazione di mercato:
$1.85B
Reddito:
$2.00B
Utile/perdita netta:
$-119.19M
Rapporto P/E:
-14.84
EPS:
-2.19
Flusso di cassa netto:
$-61.88M
1 W Prestazione:
-14.94%
1M Prestazione:
-13.84%
6M Prestazione:
-17.97%
1 anno Prestazione:
-46.41%
Intervallo 1D:
$30.39
$34.15
Intervallo di 1 settimana:
$30.39
$38.19
Portata 52W:
$30.39
$62.79
Enovis Corp Stock (ENOV) Company Profile
Nome
Enovis Corp
Settore
Industria
Telefono
(302) 252-9160
Indirizzo
2711 CENTERVILLE ROAD, WILMINGTON
Confronta ENOV con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ENOV
Enovis Corp
|
32.50 | 1.85B | 2.00B | -119.19M | -61.88M | -2.19 |
|
ABT
Abbott Laboratories
|
124.86 | 216.55B | 41.95B | 13.40B | 6.35B | 7.65 |
|
SYK
Stryker Corp
|
345.34 | 142.48B | 22.60B | 2.99B | 3.49B | 7.76 |
|
BSX
Boston Scientific Corp
|
91.54 | 132.67B | 16.75B | 1.85B | 2.37B | 1.25 |
|
MDT
Medtronic Plc
|
83.15 | 106.28B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
69.00 | 40.63B | 5.72B | 4.17B | 259.90M | 6.97 |
Enovis Corp Stock (ENOV) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-10-03 | Iniziato | JMP Securities | Mkt Outperform |
| 2024-06-13 | Iniziato | JP Morgan | Neutral |
| 2024-02-13 | Iniziato | Stephens | Overweight |
| 2024-01-22 | Iniziato | UBS | Buy |
| 2024-01-03 | Iniziato | William Blair | Outperform |
| 2023-12-15 | Reiterato | Needham | Buy |
| 2023-10-20 | Iniziato | ROTH MKM | Buy |
| 2023-06-26 | Iniziato | Needham | Buy |
| 2023-05-12 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2022-10-12 | Iniziato | Jefferies | Buy |
| 2022-10-11 | Iniziato | Goldman | Buy |
| 2022-09-12 | Iniziato | Canaccord Genuity | Buy |
| 2022-09-12 | Iniziato | Evercore ISI | Outperform |
| 2022-06-28 | Iniziato | Argus | Hold |
| 2022-06-27 | Ripresa | Loop Capital | Buy |
| 2022-06-16 | Iniziato | Wells Fargo | Equal Weight |
Mostra tutto
Enovis Corp Borsa (ENOV) Ultime notizie
Enovis appoints Damien McDonald as CEO - MedTech Dive
Enovis Appoints Damien McDonald CEO, Reaffirms Q1 Guidance Amid Strategic Growth Push - insights.citeline.com
Canaccord maintains Buy rating and $75 target for Enovis stock - Investing.com Australia
Enovis Receives Buy Rating Amidst Strategic Leadership Change and Strong Financial Projections - TipRanks
Enovis’s Promising Future: Buy Rating Backed by Strategic Leadership and Positive Financial Outlook - TipRanks
Enovis names Damien McDonald as new CEO starting May 12 By Investing.com - Investing.com Canada
Enovis (ENOV) Appoints New CEO and Confirms Revenue Forecast - GuruFocus
Enovis Names Damien McDonald as New CEO to Drive Next Growth Chapter - MSN
Analysts Have Conflicting Sentiments on These Industrial Goods Companies: Enovis (ENOV) and Auckland International Airport Limited (OtherACKDF) - The Globe and Mail
Enovis names Damien McDonald as CEO, succeeding Matt Trerotola - TipRanks
Strategic Leadership and Financial Stability Drive Buy Rating for Enovis - TipRanks
Enovis Announces Appointment of Damien McDonald as Chief Executive Officer - Ortho Spine News
Enovis Corporation Reiterats Earnings Guidance for the First Quarter of 2025 - MarketScreener
Former LivaNova CEO to take corner office at Enovis - MassDevice
Enovis names McDonald as CEO - MSN
Enovis Names Damien McDonald as Chief Executive; Reaffirms Q1 Revenue Guidance - MarketScreener
Enovis Appoints Damien McDonald as Chief Executive Officer - citybiz
Enovis names Damien McDonald as new CEO starting May 12 - Investing.com India
Enovis Appoints Damien McDonald as New CEO - TipRanks
Enovis Announces Appointment Of Damien Mcdonald As Chief Executive Officer - MarketScreener
Medical Device Expert Takes Helm at Enovis: Former LivaNova CEO to Drive Growth - Stock Titan
Enovis Corporation (NYSE:ENOV) Looks Inexpensive But Perhaps Not Attractive Enough - simplywall.st
2 Healthcare Stocks with Solid Fundamentals and 1 to Turn Down - The Globe and Mail
Enovis Showcases Innovative Foot and Ankle Solutions at ACFAS Conference - MSN
Enovis™ to Exhibit Extensive Range of Foot & Ankle Solutions at ACFAS 2025 - GlobeNewswire
Enovis, Foundation Surgical and J&J MedTech Named Winners of OMTEC® Awards, Honoring Excellence in Orthopedic Innovation - Ortho Spine News
Revolutionary Bunion Surgery System Leads Enovis's Major Product Launch at ACFAS 2025 - Stock Titan
Enovis : trade; Publishes 2024 Corporate Social Responsibility Report -March 24, 2025 at 04:41 pm EDT - MarketScreener
Enovis Corp (ENOV) Stock Price Up 1.77% on Mar 19 - GuruFocus.com
Enovis Plans Leadership Change - The Healthcare Technology Report.
Enovis CEO Matthew Trerotola Announces Retirement Plan - TipRanks
Positive Outlook for Enovis: Strong Market Position and Strategic Growth Initiatives - TipRanks
Diabetic Footwear Market Demand : Identifying Key Growth Opportunities By 2032 | Enovis companies, Pilgrim - EIN News
Enovis Corporation Announces Participation in Upcoming Investor Conferences - MSN
Enovis Positioned for Growth: Buy Rating Highlights Strategic Execution and Undervaluation - TipRanks
Enovis to Participate in Upcoming Investor Conferences - The Manila Times
Enovis Leadership Reveals Investor Conference Schedule: Key Dates for Healthcare Investors - StockTitan
Enovis Hits Another 52-Week Low. Here’s Why It’s A Contrarian Buy. - Barchart
Enovis Hits Another 52-Week Low. Here’s Why It’s a Contrarian Buy. - TradingView
Enovis : rsquo; Louie Vogt on driving recon growth past $1B with M&A, knee breakthroughs, and foot and ankle expansion - Marketscreener.com
Enovis Corporation Reports Strong Growth Amid Challenges - MSN
William Blair Issues Optimistic Outlook for Enovis Earnings - MarketBeat
Enovis (NYSE:ENOV) Issues FY 2025 Earnings Guidance - MarketBeat
Enovis (ENOV) Q4 Earnings and Revenues Surpass Estimates - MSN
Enovis Positioned for Growth: Buy Rating Backed by Strong Sales, Product Launches, and Attractive Valuation - TipRanks
Enovis (NYSE:ENOV) Reaches New 1-Year Low on Analyst Downgrade - MarketBeat
Enovis Reports Strong 2024 Sales Growth Despite Goodwill Impairment Charge - MSN
Enovis Corp Azioni (ENOV) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.40%
0.07%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):